Increased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumor

Biochemical and Biophysical Research Communications

Volumn 374, Issue 2, 2008, Pages 198-203

  Fan, Jun Kai ^a   Xiao, Tian ^a   Gu, Jin Fa ^a   Wei, Na ^a   He, Ling Feng ^a   Ding, Miao ^a   Liu, Xin Yuan ^a,b  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Mutant kringle 5; Oncolytic adenovirus; Tumor inhibition

Indexed keywords

ARGININE; LEUCINE; MUTATED KRINGLE 5 PROTEIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS ZD 55; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CHORIOALLANTOIS; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; HETEROZYGOTE; HUMAN; HUMAN CELL; LIFESPAN; MOUSE; NEURAL TUBE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; UMBILICAL VEIN; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INHIBITION; VIRUS MUTANT; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE THERAPY; HUMANS; MICE; MICE, NUDE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PEPTIDE FRAGMENTS; PLASMINOGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS MUSCULUS;

EID: 48349137609     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.07.005     Document Type: Article

References (22)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
2. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6 (2000) 389-395
3. Chavakis E., and Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 887-893
4. Cao R., Wu H.L., Veitonmaki N., Linden P., Farnebo J., Shi G.Y., and Cao Y. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 96 (1999) 5728-5733
5. Brower V. Tumor angiogenesis-new drugs on the block. Nat. Biotechnol. 17 (1999) 963-968
6. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs 58 (1999) 17-38
7. Griffioen A.W., and Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52 (2000) 237-268
8. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
9. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
10. Castellino F.J., and McCance S.G. The kringle domains of human plasminogen. Ciba Found. Symp. 212 (1997) 46-60 (Discussion 60-45)
11. Cao Y., Chen A., An S.S., Ji R.W., Davidson D., and Llinas M. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. 272 (1997) 22924-22928
12. Ji W.R., Barrientos L.G., Llinas M., Gray H., Villarreal X., DeFord M.E., Castellino F.J., Kramer R.A., and Trail P.A. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem. Biophys. Res. Commun. 247 (1998) 414-419
13. Lu H., Dhanabal M., Volk R., Waterman M.J., Ramchandran R., Knebelmann B., Segal M., and Sukhatme V.P. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem. Biophys. Res. Commun. 258 (1999) 668-673
14. Zhang D., Kaufman P.L., Gao G., Saunders R.A., and Ma J.X. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44 (2001) 757-765
15. Davidson D.J., Haskell C., Majest S., Kherzai A., Egan D.A., Walter K.A., Schneider A., Gubbins E.F., Solomon L., Chen Z., Lesniewski R., and Henkin J. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res. 65 (2005) 4663-4672
16. Chang Y., Mochalkin I., McCance S.G., Cheng B., Tulinsky A., and Castellino F.J. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry 37 (1998) 3258-3271
17. Kirn D.H., and McCormick F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today 2 (1996) 519-527
18. Russell S.J. Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol. 5 (1994) 437-443
19. Zhang Z.L., Zou W.G., Luo C.X., Li B.H., Wang J.H., Sun L.Y., Qian Q.J., and Liu X.Y. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 13 (2003) 481-489
20. Pei Z., Chu L., Zou W., Zhang Z., Qiu S., Qi R., Gu J., Qian C., and Liu X. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 39 (2004) 1371-1381
21. Zhao L., Gu J., Dong A., Zhang Y., Zhong L., He L., Wang Y., Zhang J., Zhang Z., Huiwang J., Qian Q., Qian C., and Liu X. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer,. Hum. Gene Ther. 16 (2005) 845-858
22. Zhao L., Dong A., Gu J., Liu Z., Zhang Y., Zhang W., Wang Y., He L., Qian C., Qian Q., and Liu X. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 13 (2006) 1011-1022